Morgan Stanley’s Eterna Therapeutics ERNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1
| Closed | -$36 | – | 8353 |
|
|
2025
Q4 | $36 | Sell |
1
-2
| -67% | -$68 | ﹤0.01% | 7963 |
|
|
2025
Q3 | $84 | Sell |
3
-19
| -86% | -$753 | ﹤0.01% | 7715 |
|
|
2025
Q2 | $1.02K | Buy |
+22
| New | +$1.58K | ﹤0.01% | 7333 |
|
|
2024
Q4 | – | Hold |
0
| – | -$53 | – | 8002 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 7560 |
|
|
2024
Q2 | – | Hold |
0
| – | – | – | 7366 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 7357 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 7357 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 7436 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 7487 |
|
|
2023
Q1 | – | Sell |
-4
| Closed | -$6.02K | – | 7527 |
|
|
2022
Q4 | $4.39K | Buy |
4
+2
| +100% | +$2.82K | ﹤0.01% | 7177 |
|
|
2022
Q3 | $3K | Sell |
2
-3
| -60% | -$10.3K | ﹤0.01% | 7377 |
|
|
2022
Q2 | $21K | Sell |
5
-92
| -95% | -$660K | ﹤0.01% | 6957 |
|
|
2022
Q1 | $1.49M | Buy |
97
+24
| +33% | +$455K | ﹤0.01% | 4725 |
|
|
2021
Q4 | $2.27M | Buy |
73
+72
| +7,200% | +$3.92M | ﹤0.01% | 4478 |
|
|
2021
Q3 | $97K | Sell |
1
-1
| -50% | -$86.3K | ﹤0.01% | 6399 |
|
|
2021
Q2 | $299K | Buy |
+2
| New | +$288K | ﹤0.01% | 5811 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 7502 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 7054 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 6759 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6673 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6618 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6626 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6731 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6687 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6637 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6589 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6550 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6604 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6494 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6431 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6517 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6548 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6614 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6699 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6536 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6670 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6396 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6393 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6436 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 6346 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 6272 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 6297 |
|
Other funds holding ERNA
BL
DIG
XT
WAM
Morgan Stanley's ERNA Position: Q1 2026 in Review
Morgan Stanley sold out of Eterna Therapeutics (ERNA) in Q1 2026, closing a stake of 1 share — an estimated $36 sold.
Morgan Stanley first reported a position in ERNA in Q2 2021 and held it in 10 quarters. The position peaked at $2.27M in Q4 2021. 15 funds tracked by Wall St. Rank hold ERNA as of Q1 2026.
- Morgan Stanley reported no remaining Eterna Therapeutics position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 1 Eterna Therapeutics share in Q1 2026, an estimated $36.
- Morgan Stanley first reported a position in Eterna Therapeutics in Q2 2021 and held it in 10 quarters.
- Morgan Stanley's Eterna Therapeutics position peaked at $2.27M in Q4 2021.
- 15 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.